Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sight Sciences, Inc.

4.06
-0.2100-4.92%
Post-market: 4.060.00000.00%16:11 EDT
Volume:225.32K
Turnover:944.86K
Market Cap:209.88M
PE:-4.16
High:4.36
Open:4.32
Low:4.06
Close:4.27
Loading ...

Sight Sciences Is Maintained at Buy by UBS

Dow Jones
·
28 Jan

UBS Adjusts Price Target on Sight Sciences to $5 From $5.50, Keeps Buy Rating

MT Newswires Live
·
27 Jan

Sight Sciences price target lowered to $5 from $5.50 at UBS

TIPRANKS
·
26 Jan

Promising US Penny Stocks To Consider In January 2025

Simply Wall St.
·
25 Jan

Sight Sciences Inc : Morgan Stanley Cuts Target Price to $3.00 From $4.00

THOMSON REUTERS
·
23 Jan

Citi Remains a Hold on Sight Sciences (SGHT)

TIPRANKS
·
17 Jan

Sight Sciences price target lowered to $3 from $5 at Lake Street

TIPRANKS
·
15 Jan

Stifel Nicolaus Sticks to Their Buy Rating for Sight Sciences (SGHT)

TIPRANKS
·
15 Jan

Lake Street Sticks to Its Hold Rating for Sight Sciences (SGHT)

TIPRANKS
·
14 Jan

Sight Sciences sees Q4 revenue $18.9M-19.1M, consensus $20.29M

TIPRANKS
·
14 Jan

Sight Sciences Announces Preliminary Q4 2024 Revenue Of $18.9M-$19.1M; Surgical Glaucoma Revenue Up 9%; FY24 Revenue $79.7M-$79.9M, Surgical Glaucoma Up 2%

Benzinga
·
14 Jan

Sight Sciences Inc: Q4 Total REV Is Expected to Be in the Range of $18.9 Mln to $19.1 Mln

THOMSON REUTERS
·
14 Jan

Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2024 Financial Highlights

THOMSON REUTERS
·
14 Jan

Sight Sciences Inc Q4 REV View $20.3 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
14 Jan

Sight Sciences Reports Positive OMNI Surgical System Data From 36-Month Study

MT Newswires Live
·
08 Jan

Sight Sciences study demonstrates benefits of OMNI system for managing POAG

TIPRANKS
·
08 Jan

Sight Sciences Announces Real-World 36-Month Study Confirming Long-Term Effectiveness of Standalone OMNI Surgical System in Managing Primary Open-Angle Glaucoma

GlobeNewswire
·
08 Jan